Academic Journal

CDK4/6 inhibition promotes antitumor immunity through the induction of T-cell memory

التفاصيل البيبلوغرافية
العنوان: CDK4/6 inhibition promotes antitumor immunity through the induction of T-cell memory
المؤلفون: Lelliott, E.J., Kong, I.Y., Zethoven, M., Ramsbottom, K.M., Martelotto, L.G., Meyran, D., Zhu, J.J., Costacurta, M., Kirby, L., Sandow, J.J., Lim, L., Dominguez, P.M., Todorovski, I., Haynes, N.M., Beavis, P.A., Neeson, P.J., Hawkins, E.D., McArthur, G.A., Parish, I.A., Johnstone, R.W.
المصدر: http://dx.doi.org/10.1158/2159-8290.cd-20-1554.
بيانات النشر: American Association for Cancer Research (AACR)
سنة النشر: 2021
المجموعة: The University of Adelaide: Digital Library
مصطلحات موضوعية: Cell Line, Tumor, Animals, Humans, Mice, Breast Neoplasms, Piperazines, Pyridines, Antineoplastic Agents, Protein Kinase Inhibitors, Xenograft Model Antitumor Assays, Female, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Memory T Cells
الوصف: Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor-positive breast cancer and are currently under evaluation across hundreds of clinical trials for other cancer types. The clinical success of these inhibitors is largely attributed to well-defined tumor-intrinsic cytostatic mechanisms, whereas their emerging role as immunomodulatory agents is less understood. Using integrated epigenomic, transcriptomic, and proteomic analyses, we demonstrated a novel action of CDK4/6 inhibitors in promoting the phenotypic and functional acquisition of immunologic T-cell memory. Short-term priming with a CDK4/6 inhibitor promoted long-term endogenous antitumor T-cell immunity in mice, enhanced the persistence and therapeutic efficacy of chimeric antigen receptor T cells, and induced a retinoblastoma-dependent T-cell phenotype supportive of favorable responses to immune checkpoint blockade in patients with melanoma. Together, these mechanistic insights significantly broaden the prospective utility of CDK4/6 inhibitors as clinical tools to boost antitumor T-cell immunity. SIGNIFICANCE: Immunologic memory is critical for sustained antitumor immunity. Our discovery that CDK4/6 inhibitors drive T-cell memory fate commitment sheds new light on their clinical activity, which is essential for the design of clinical trial protocols incorporating these agents, particularly in combination with immunotherapy, for the treatment of cancer. ; Emily J. Lelliott, Isabella Y. Kong, Magnus Zethoven, Kelly M. Ramsbottom, Luciano G. Martelotto, Deborah Meyran, Joe Jiang Zhu, Matteo Costacurta, Laura Kirby, Jarrod J. Sandow, Lydia Lim, Pilar M. Dominguez, Izabela Todorovski, Nicole M. Haynes, Paul A. Beavis, Paul J. Neeson, Edwin D. Hawkins, Grant A. McArthur, Ian A. Parish, Ricky W. Johnstone, Jane Oliaro, Karen E. Sheppard, Conor J. Kearney, and Stephin J. Vervoort
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 2159-8274
2159-8290
Relation: http://purl.org/au-research/grants/nhmrc/1100189; http://purl.org/au-research/grants/nhmrc/1139626; http://purl.org/au-research/grants/nhmrc/1140187; http://purl.org/au-research/grants/nhmrc/GNT1165591; http://purl.org/au-research/grants/nhmrc/454569; http://purl.org/au-research/grants/nhmrc/GNT1178339; http://purl.org/au-research/grants/nhmrc/159488; Cancer Discovery, 2021; 11(10):2582-2601; https://hdl.handle.net/2440/134515; Martelotto, L.G. [0000-0002-9625-1183]
DOI: 10.1158/2159-8290.CD-20-1554
الاتاحة: https://hdl.handle.net/2440/134515
https://doi.org/10.1158/2159-8290.CD-20-1554
Rights: ©2021 American Association for Cancer Research
رقم الانضمام: edsbas.CA31FCC2
قاعدة البيانات: BASE
الوصف
تدمد:21598274
21598290
DOI:10.1158/2159-8290.CD-20-1554